STTR Funding for Your Start-up

Early stage start-ups are often looking for resources to advance their company and products. Start-ups from institutions like Emory are no different. The Small Business Administration’s Small Business Technology Transfer Research (STTR) program might provide a solution for these entrepreneurs. The STTR program was created in 1992. All federal agencies with extramural research budgets over certain thresholds must participate in STTR and set-aside a required portion of their funds for these programs. Currently there are five agencies with STTR programs. The intent is for domestic small businesses to participate in research and development with commercialization potential. The STTR is described as a program, “that expands funding opportunities in the federal innovation research and development arena.” The initiative is sponsored by various Federal agencies, like the National Science Foundation and the Department of Health and Human Services, with the goal of forming partnerships with the private sector through the support of commercialization of research. The STTR support fund is formed by the participating agencies which have to set aside portions of their budget for small business technology transfer research awards. After an agency accepts a small business’ proposal for funding, it enters into the three-phased program. In the first phase, the

Continue reading

SBIR Funding for Your Start-up

Entrepreneurs and small business owners at Emory who are looking for an alternate source of income can tap into Small Business Innovation Research (SBIR) funds administered by the federal government. In association with some of its largest and most influential agencies, the U.S. government is looking to support innovation and growth by funding the newly seeded businesses involved in research and development. The SBIR program was founded in 1977 when two men, Roland Tibbetts and Senator Edward Kennedy, recognized the importance of small business growth in the economy. Birthed out of the National Science Foundation, success in the first few years led to its adoption by the Small Business Administration which mandated that government agencies should set aside SBIR funding. Each federal agency, which have research and development budgets greater than $100 million, are required to commit at least 2.8 percent of these budgets to SBIR funding. The eleven agencies that participate in the program have their own guidelines for acceptance under Congress’s established legislation. They are listed below along with links to their SBIR pages: Department of Agriculture National Institute of Standards and Technology National Oceanic and Atmospheric Administration Department of Defense Department of Education Department of Energy Department

Continue reading

Funding Your Start-up

Every start-up founder hopes one day for their project/technology to succeed, reach the market, and quite often improve patients’ lives. Funding is just one of the critical hurdles in the early stages. The following list will explain just a few of the many sources of investment. Bootstrapping: Sometimes the best source of funding for a small business can be its entrepreneur(s). Bootstrap financing is starting a business with minimal capital mostly provided by a person or group of people from the start-up team. This often includes dipping into savings, retirement, personal loans (including home equity), or accessing credit cards. This is the most common type of financing in small business. Given the costs involved with a pharmaceutical or medical device company this approach can be challenging, but for a software company can be a successful approach. Friends and Family: Sometimes the best way to gain access to funding is through the people who are closest to you. Tapping your family and friends to invest in your start-up can strain relationships and is only advisable if they fully understand the risks involved with your start-up. Forbes suggests that a loan from friends and family is sort of like a “grant with

Continue reading

Inventor Becomes Patient: My Tool Was Like a Trusted Friend Telling Me What Was Wrong

Ernest V. Garcia, PhD, or better known as Ernie, is an endowed professor in cardiac imaging and the director of Emory’s Nuclear Cardiology R&D Laboratory. He specializes in medical imaging and bioinformatics, particularly quantitative analysis of cardiac images. Ernie has received numerous awards and honors but to highlight a few he was named a Medical Imaging Industry Top 10 Nuclear Medicine Researcher by the Medical Imaging Magazine and was named to the Council of Distinguished Investigators of the Academy of Radiology Research. What lead you to pursue cardiac imaging as part of your profession? I was trained as a scientist, a physicist. And I had a great deal of experience with computers and computer software, which was unusual for a scientist working in the 1960s. Back then, cardiology was the most quantitative modality that existed and it probably still is today. Meaning that the cardiologists were and are interested in numbers and quantitative data. So, I thought that I would apply my scientific background to the art of image interpretation. Who has impacted you the most in your career and why? That’s a tough question, there is the physicist part of me. So, I am definitely motivated by the life

Continue reading

It Started in My Basement, Now it Improves Patients Lives

Charles M. Epstein, MD, or “Chip” as he’s been known since childhood, is a professor of neurology specializing in epilepsy and the founder of  the Laboratory for Transcranial Magnetic Stimulation (TMS). He is also a co-inventor for the technology that is utilized by Emory partner Neuronetics, Inc in their NeuroStar TMS Therapy® for treating depression. Neuronetics has safely administered more than 10,000 NeuroStar TMS Therapy® treatments with clinically significant results: among patients studied, 54 percent responded to the therapy and 33 percent found their depression in remission. Neurostar wasn’t the first technology you were involved with. Could you tell us about some of your previous technologies? NeoControl was actually the first magnetic technology that went on the market thanks to Neotonus. This company was the first to develop TMS to treat urinary incontinence in women. World wide, women have been more prone to urinary incontinence than men. This was especially true after childbirth and before modern obstetrics. Using electromagnetics, treatment is much more comfortable than prior methods. The magnets work right through clothing and are essentially painless. This was the foundation of Neotonus’ technology, NeoControl. Unlike brain stimulation, TMS in the pelvic area takes even more power and without our

Continue reading

From the Director: Advise to Faculty Considering a Start-up

What is the biggest challenge start-ups face today? The biggest challenge our new startups face is finding an entrepreneur with time and business expertise. There are so many resources available to entrepreneurs today that weren’t here just a few years ago, but it still takes time to explore them, have a conversation, identify an opportunity and pursue it. We often talk about how the lack of business experience handicaps a well-intentioned faculty entrepreneur, but the reality is that their availability is just as restrictive when they have full-time commitments to teach, research and/or see patients. On the other hand, attracting an external entrepreneur to a nascent startup is just as difficult, so we often have to rely on a faculty entrepreneur for some period of time. What are some main goals researchers have when contemplating forming a start-up? A common goal is simply attaining additional funding to move their technology forward. Researchers, wanting to become entrepreneurs, talk to a lot of people about their technology and they often hear, “It’s an interesting idea, but have you created or tested a prototype yet?” Quite often researchers have to form a company just to find translational funding to do this kind of

Continue reading

Startups: Words from the Trenches – Part 7

Each year OTT helps launch high-quality start-up companies based on discoveries made by Emory faculty or staff. Over the past few months, OTT set out to interview a selection of the entrepreneurs and VCs we have worked with and pick their brains about what it takes to make a successful startup venture. To visit Part 1: here To visit Part 2: here To visit Part 3: here To visit Part 4: here To visit Part 5: here To visit Part 6: here What key items do you feel contribute to a successful startup? Stephen Snowdy (CEO; Venture Advisory Board Member at Emory University): In medical science startups, it is critical to have the best people possible analyzing and vetting the technology, the best people possible building the opportunity into a fundable story, and the best people possible selling the opportunity to funding sources; in other words, human capital is just as important as all of the science and medical business issues and is one of the most difficult resources to build. Extreme capital efficiency is also critical in the early stages owing to the dearth of early-stage funding that is available. Objectivity around decision-making is absolutely key. When and how

Continue reading

Startups: Words from the Trenches – Part 6

Each year OTT helps launch high-quality start-up companies based on discoveries made by Emory faculty or staff. Over the past few months, OTT set out to interview a selection of the entrepreneurs and VCs we have worked with and pick their brains about what it takes to make a successful startup venture. To visit Part 1: here To visit Part 2: here To visit Part 3: here To visit Part 4: here To visit Part 5: here What do you see as the biggest changes over the past decade for start-ups? Stephen Snowdy (CEO; Venture Advisory Board Member at Emory University): The biggest change over the past decade is the dramatic decline in funding that is available for early-stage startups. The traditional way to fund innovation was that the government subsidized research and discovery through grants, venture capitalists invested in further risk reduction at the startup level, and ultimately passed the risk off to either the public markets or to large corporations. Government funding for research and funding available for venture capital have dropped to levels not seen in decades. In addition, on a macro-level, the traditional venture capital model has not been a successful financial model, so it is

Continue reading

Startups: Words from the Trenches – Part 5

Each year OTT helps launch high-quality start-up companies based on discoveries made by Emory faculty or staff. Over the past few months, OTT set out to interview a selection of the entrepreneurs and VCs we have worked with and pick their brains about what it takes to make a successful startup venture. To visit Part 1: here To visit Part 2: here To visit Part 3: here To visit Part 4: here How did you go about building a team? Michael Lee (Chairman & CEO of the Emory start-up Syntermed): Assuming you’ve made the correct/best hire, understanding every team members’ personal and professional goals and aspirations within the context of the company’s corporate goals with an executive commitment to make sure these are fulfilled. Hire slowly, fire quickly. How did you know which technology is a good opportunity for starting a company? Stephen Snowdy (CEO; Venture Advisory Board Member at Emory University): I look for technologies that have the potential to materially change clinical outcomes for patients or that will significantly reduce the cost of healthcare. Also important are the quality of the data, strong international patent positioning, attractiveness in the financial markets (fundability), the height of the regulatory hurdles,

Continue reading

From Academic Researcher to Startup Scientist: Leaving the Lab to Pursue Your Innovation

Each year OTT helps launch a number of startup companies based around discoveries made by Emory faculty or staff.  In most of those cases the faculty member remains at the university as a researcher or clinician while he or she simultaneously serves in some type of advisory role for the company. In some instances however faculty leave the university environment to strike out into the exciting world of startups. In this piece we talk to former Emory professor Harriet Robinson, PhD, who is now the Chief Science Officer at GeoVax, an Emory startup developing HIV vaccines based on previous work from her lab. Before you created the HIV vaccine technology, had you ever given much thought to the commercialization of university discoveries? Yes, I had previously wanted to commercialize a different vaccine technology that I discovered while at another university. At that time it was not possible due to state restrictions that limited the ability of faculty to license their own findings from the university. Those limitations stemmed from legislation created to curb legislators from awarding contracts to themselves or relatives. What made you decide to follow the technology to a startup company rather than stay in academic research at

Continue reading

Start-ups: Words from the Trenches – Part 4

Each year OTT helps launch high-quality start-up companies based on discoveries made by Emory faculty or staff. Over the past few months, OTT set out to interview a selection of the entrepreneurs and VCs we have worked with and pick their brains about what it takes to make a successful startup venture. To visit Part 1: here To visit Part 2: here To visit Part 3: here How has OTT contributed to the success of your start-up? Michael Lee (Chairman & CEO of the Emory start-up Syntermed): By understanding that success does not end with the execution of an agreement, but rather that the execution of an agreement can produce success. Also through ancillary marketing and PR awareness that only the Emory brand and reach can command. Terence Walts (President & CEO of two Emory start-ups, Transfusion & Transplantation Technologies (“3Ti”) and Cambium Medical Technologies): By continuing to be very supportive and patient as well as continuing to serve as an extraordinarily important “co-partner and valued stakeholder” in these ventures. I continue to view OTT as an important part of our team. OTT is also excellent in getting the word out to the local entrepreneurial community on emerging Emory technologies,

Continue reading

Start-ups: Words from the Trenches – Part 3

Each year OTT helps launch high-quality start-up companies based on discoveries made by Emory faculty or staff. Over the past few months, OTT set out to interview a selection of the entrepreneurs and VCs we have worked with and pick their brains about what it takes to make a successful startup venture. To visit Part 1: here To visit Part 2: here What was your biggest fear/apprehension going into starting your first company? Ed Cannon (President & CEO of the Emory start-up NovAb): Thirty years ago, when I started, the only “rule” was “there are no rules,” which allowed us to make up the rules as needed. My biggest fear and anxiety then was recruiting talented scientists as I knew the technology was well-developed and the commercial opportunities were obvious. My business partner’s biggest fear on the other hand was obtaining adequate financing for the company. We were fortunate on both counts as Boston was, and continues to be, overflowing with scientific and technical talent. Local venture groups were likewise flush with cash from successes and looking for the next “Big Thing.” In fact Boston, like the Bay Area, was rich with all of the infrastructure needed to support the

Continue reading

Start-ups: Words from the Trenches – Part 2

Each year OTT helps launch high-quality start-up companies based on discoveries made by Emory faculty or staff. Over the past few months, OTT set out to interview a selection of the entrepreneurs and VCs we have worked with and pick their brains about what it takes to make a successful startup venture. To visit Part 1: here What do you recommend/what is a piece of advice for someone looking to start a company? Daniel White (President & CEO of the joint Emory/Georgia Tech start-up Clearside Biomedical): Take an honest assessment of who you are. What are the things that may hold you back. 1) Is it experience? (Investors will want someone who has done this before). 2) Does the intellectual property stand alone or are you only solving an incremental problem? 3) Are you requiring too much money to reach success? 4) Do you have enough and the right human capital supporting the project? (I have seen many a company fail because the president is too stingy with stock to bring in the right talent to get the job done.) As I look back at my career as an entrepreneur, there are four characteristics that I believe separate the people who

Continue reading

Start-ups: Words from the Trenches – Part 1

Each year OTT helps launch high-quality start-up companies based on discoveries made by Emory faculty or staff. Over the past few months, OTT set out to interview a selection of the entrepreneurs and VCs we have worked with and pick their brains about what it takes to make a successful startup venture. What got you thinking about becoming an entrepreneur and starting/joining a start-up? Terence Walts (President & CEO of two Emory startups, Transfusion & Transplantation Technologies (“3Ti”) and Cambium Medical Technologies): I headed the department of New Business Development at CIBA Vision until 1998. During that time, I did due diligence on a very early stage start-up concerning refractive surgery in which CIBA ultimately invested $6 million. I got so excited about this start-up, its potential, and the opportunity to help create and build something new that for my last three years at CIBA, I got an agreement to vacate my business development responsibilities and work full-time with the management team of this start-up with plans to join them full-time after 1998. I took this risk because I believed in the technology, the founders, and the opportunity–and believed that my personal business development and market focus skills had uncovered

Continue reading